stockrow
Friday 6 November 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
76.08
11.28
+17.41%
Follow CGON
Alert me
CG Oncology, Inc. (CGON) Gross margin
CG Oncology, Inc.'s gross margin over the twelve months to 30 September 2026 was 0.00%, up 15.0 percentage points from fiscal 2025 (−15.0%). That is below the Biotechnology industry median of 65.2% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | −15.0% | (115.02) |
| FY2024 | 100.0% | 0.00 |
| FY2023 | 100.0% | 0.00 |
| FY2022 | 100.0% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 0.00% | 239.24 |
| Jun 2026 | −239.2% | (65.74) |
| Mar 2026 | −173.5% | (141.29) |
| Dec 2025 | −32.2% | (37.55) |
| 9 more quarters | Free account |
Gross margin against peers
| Company | Gross margin |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 95.2% |
| PTCT PTC Therapeutics, Inc. compare | 93.2% |
| MIRM Mirum Pharmaceuticals, Inc. compare | 81.7% |
| KOD Kodiak Sciences Inc. compare | 0.00% |
| IMVT Immunovant, Inc. compare | 0.00% |
| SRRK Scholar Rock Holding Corporation compare | 0.00% |
| CGON CG Oncology, Inc. | −85.2% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| MANE Veradermics Incorporated compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on CGON
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement